M. Rogers, S. Gordon, H. Benford
Jun 15, 2000
Citations
34
Influential Citations
926
Citations
Quality indicators
Journal
Cancer
Abstract
Bisphosphonates currently are the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor‐associated osteolysis and hypercalcemia, Paget's disease, and osteoporosis. These compounds have high affinity for calcium and therefore target to bone mineral, where they appear to be internalized selectively by bone‐resorbing osteoclasts and inhibit osteoclast function.